中國幸福投資(08116.HK)2018年前三季度虧損2.88億港元
格隆匯11月3日丨中國幸福投資(08116.HK)公佈,截至2018年9月30日止9個月,來自持續經營業務收益1.75億港元,同比增長7.99%;毛利3750.9萬港元,同比下降28.50%;公司擁有人應占虧損2.88億港元(含已終止經營業務),上年同期純利348.3萬港元;每股基本及攤薄虧損9.49港仙。
收益約6855萬港元乃來自零售及批發酒類、雪茄及高爾夫產品,約1.05億港元乃產生自鐘錶及珠寶買賣業務,以及135萬港元乃產生自貸款利息收入。
2018年的變動主要源於失去成都附屬公司的控制權,導致取消綜合入賬附屬公司的虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.